You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Electronics and computational hardware for ultra-high channel count electrophysio

    SBC: Leaflabs, LLC            Topic: 101

    DESCRIPTION provided by applicant The advent of in vivo multielectrode recording has indicated the importance of recording from large populations of neurons As a result there is much interest in creating new kinds of in vivo multielectrode arrays including the polytrode new kinds of microfabricated electrode arrays and new kinds of ultradense D electrode array And yet innovation on the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Fluorescence Lifetime Dynamics to Understand Brain Neural Activities and Behavior

    SBC: CHISQUARE BIOIMAGING LLC            Topic: 500

    DESCRIPTION provided by applicant The overall objective of the proposed project is to create a compact robust and easy to use device that is capable of sensitive and quantitative detection of fluorescence lifetime indicators of physiological and biochemical dynamics deep in the brain of a freely moving mouse In contrast to fluorescence intensity based methods fluorescence lifetime can delin ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Optopatch: high-throughput all-optical electrophysiology for neural recording

    SBC: Q-State Biosciences, Inc.            Topic: 102

    DESCRIPTION provided by applicant Optopatch high throughput all optical electrophysiology for neural recording The convergence of stem cell genomic and advanced imaging technologies provides unprecedented ability to study human neural physiology in health and disease Traditionally intractable diseases schizophrenia autism Alzheimerandapos s ALS and Parkinsonandapos s are being modeled ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Transitioning Electronic Support for Public Health (ESP) from Lab to Marketplace

    SBC: Commonwealth Informatics, Inc.            Topic: 400

    DESCRIPTION provided by applicant Accurate and complete disease surveillance is critical to enable public health authorities to detect and respond to disease outbreaks epidemics and even bioterrorism events While legally required of healthcare practitioners and practices most notifiable disease reporting is still done manually or through limited automated laboratory test result reporting ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This is a collaborative proposal to develop inhibitors with reduced susceptibility to resistance and improved genotype spectrum of activity against the NS A protease of the Hepatitis C virus HCV Over three percent of the worldandapos s population is infected with the hepatitis C virus HCV Unfortunately the current best treatment is still quite challeng ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant Leptospirosis a zoonotic disease is an important public health problem worldwide It is caused by spirochete bacteria belonging to nine species and more than serovars of the genus Leptospira In the US there is increasing awareness of the importance of leptospirosis as the cause of disease among inner city populations military personnel and individuals ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Selective agents against C. difficile infection

    SBC: NOVOBIOTIC PHARMACEUTICALS, LLC            Topic: NIAID

    DESCRIPTION provided by applicant The overall goal of this project is to develop a selective antibiotic against Clostridium difficile the major agent responsible for antibiotic induced diarrhea and colitis The pathogen can be carried in healthy individuals and is kept at bay by gut symbionts Antibiotic treatment suppresses the normal flora but spores of C difficile survive germinate and ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government